Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | BCL2 | P10415 | 2/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15623779 | 1.00 | RAB9A (0.41) | RAB9AALDH1A1PKMSLC1A2KMT2A | |
| SCHEMBL1289923 | 0.92 | RAB9A (0.39) | RAB9AALDH1A1PKMSLC1A2KMT2A | |
| SCHEMBL31259418 | 0.86 | ALDH1A1 (0.46) | ALDH1A1PKMSLC1A2KMT2AMEN1 | |
| SCHEMBL1289817 | 0.80 | ALDH1A1 (0.37) | RAB9AALDH1A1PKMSLC1A2KMT2A | |
| SCHEMBL1564220 | 0.80 | ALDH1A1 (0.40) | ALDH1A1PKMSLC1A2KMT2AMEN1 | |
| SCHEMBL1514142 | 0.80 | MEN1 (0.38) | RAB9AALDH1A1KMT2AMEN1BCL2 | |
| Hydrochloric Acid SCHEMBL1289819 | 0.79 | ALDH1A1 (0.36) | ALDH1A1PKMSLC1A2KMT2AMEN1 | |
| SCHEMBL57078 | 0.77 | KMT2A (0.53) | ALDH1A1PKMSLC1A2KMT2AMEN1 | |
| SCHEMBL1564214 | 0.77 | KMT2A (0.53) | ALDH1A1PKMSLC1A2KMT2AMEN1 | |
| SCHEMBL5778952 | 0.76 | TSHR (0.39) | RAB9AALDH1A1KMT2AMEN1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | FRANKLIN RICHARD (GB) | 2012-08-09 | — | — | US | disclosed |
| US-20120184532-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2012-07-19 | — | — | US | disclosed |
| CN-102573845-A | Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof | SHIRE LLC | 2012-07-11 | — | — | CN | disclosed |
| EP-2456434-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | Shire LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| WO-2012046062-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | SHIRE, LLC (US) | 2012-04-12 | — | — | WO | disclosed |
| EP-2413937-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | Shire LLC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2011011766-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010112942-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-10-07 | — | — | WO | disclosed |
| US-7279582-B2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2007-10-09 | — | — | US | disclosed |
| US-20030100755-A1 | Retroviral protease inhibiting compounds | ABBVIE INC. | 2003-05-29 | — | — | US | disclosed |
| EP-1295874-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6472529-B2 | VIRICIDES | ABBOTT LABORATORIES | 2002-10-29 | — | — | US | disclosed |
| EP-0882024-B1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2002-02-06 | — | — | EP | disclosed |
| US-20020004503-A1 | Retroviral protease inhibiting compounds | ABBVIE INC. | 2002-01-10 | — | — | US | disclosed |
| EP-1170289-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2002-01-09 | — | — | EP | disclosed |
| US-6313296-B1 | 2-PYRROLIDINONE-1-ACETIC ACID DERIVATIVES; VIRICIDES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV); ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) TREATMENT | ABBOTT LABORATORIES | 2001-11-06 | — | — | US | disclosed |
| US-6284767-B1 | AIDS; MIXTURE WITH ENZYME INHIBITOR | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-5914332-A | NOVEL COMPOUNDS FOR USE AS HIV PROTEASE INHIBITORS IN TREATING HIV AND AIDS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | VIP, OPRL1, OPRK1 | RAB9A 2424/4885ALDH1A1 1313/4885PKM 868/4885 |
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | PEPD, VIP, GALR1 | RAB9A 1028/4885ALDH1A1 3187/4885PKM 719/4885 |
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | OPRM1, UGT1A6, UGT1A4 | RAB9A 707/4885ALDH1A1 327/4885PKM 794/4885 |
| US-20030100755-A1 | Retroviral protease inhibiting compounds | SERPINB1, PREP, TMPRSS15 | RAB9A 1974/4885ALDH1A1 2614/4885PKM 4119/4885 |
| US-20120184532-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | PEPD, VIP, GALR1 | RAB9A 1028/4885ALDH1A1 3187/4885PKM 719/4885 |
| US-20020004503-A1 | Retroviral protease inhibiting compounds | SERPINB1, PREP, TMPRSS15 | RAB9A 1974/4885ALDH1A1 2614/4885PKM 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.